Issues in pneumococcal disease and pneumococcal conjugate vaccines: Highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9-13, 2009

Vaccine

Volumn 27, Issue 50, 2009, Pages 7133-7137

  Adam, Dieter ^a  

^a NONE   (Germany)

Author keywords

PCV; Pneumococcal conjugate vaccine; Pneumococcal disease; S pneumoniae infection; Serotype 19A

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; ERYTHROMYCIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BELGIUM; CANADA; CHILD HEALTH CARE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECONOMIC ASPECT; FRANCE; GERMANY; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; MEDICAL EDUCATION; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; NETHERLANDS; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; SEROPREVALENCE; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; UNITED STATES;

COST OF ILLNESS; EUROPE; EVOLUTION, MOLECULAR; HUMANS; IMMUNIZATION SCHEDULE; ISRAEL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PUBLIC HEALTH; QUEBEC; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE;

EID: 70350746315     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.084     Document Type: Conference Paper

References (30)

1. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization. WHO position paper. Wkly Epidemiol Rec 2007;82:93-104.
2. Whitney C.G., Pilishvilli T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 9546 (2006) 1495-1502
3. Redelings M.D., Sorvillo F., Simon P., and Mascola L. Declining early childhood mortality from invasive pneumococcal disease: the impact of vaccination. Arch Pediatr Adolesc Med 159 2 (2005) 195-196
4. Tsigrelis C., Tleyieh I.M., Lahr B.D., Nyre L.M., Virk A., and Baddour L.M. Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995-2007: a population-based study. Clin Infect Dis 47 11 (2008) 1367-1371
5. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 9 (2002) 810-815
6. De Wals P., Robin E., Fortin E., Thibeault R., Ouakki M., and Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 27 11 (2008) 963-968
7. Centers for Disease Control and Prevention (CDC). Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997-2006. MMWR Morb Mortal Wkly Rep 2009;58(1):1-4.
8. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edward K.M., and Griffin M.R. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 9568 (2007) 1179-1186
9. Zhou F., Kyaw M.H., Shefer A., Winston C.A., and Nuorti J.P. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 161 12 (2007) 1162-1168
10. Kyaw M.H., Lynfield R., Schaffner W., Craig A.S., Hadler J., Reingold A., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumonia [published correction appears in N Engl J Med 2006; 355(6):638]. N Engl J Med 354 14 (2006) 1455-1463
11. Millar E.V., O'Brien K.L., Watt J.P., Bronsdon M.A., Dallas J., Whitney C.G., et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 43 1 (2006) 8-15
12. Ghaffar F., Barton T., Lozano J., Muniz L.S., Hicks P., Gan V., et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 39 7 (2004) 930-938
13. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54:893-7.
14. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008;57:144-8.
15. Moore M.R., Gertz Jr. R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 197 7 (2008) 1016-1027
16. Choi E.H., Kim S.H., Eun B.W., Kim S.J., Kim N.H., Lee J., et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 14 2 (2008) 275-281
17. Dagan R., Givon-Lavi N., Leibovitz E., Greenberg D., and Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 199 6 (2009) 776-785
18. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360 (2009) 244-256
19. Zhou F., Shefer A., Kong Y., and Nuorti J.P. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121 (2008) 253-260
20. Vestrheim D.F., Løvoll Ø., Aaberge I.S., Caugant D.A., Hoiby E.A., Bakke H., et al. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26 (2008) 3277-3281
21. Dortet L, Ploy M-C, Varon E, Poyart C, Raymond J., Epidemiology of Streptococcus pneumoniae infections in Paris area: predominance of serotype 19a. Poster presented at: 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
22. Gonzalez-Martinez F, Saavedra-Lozano J, Adrian J, Santos-Sebastian M, Chimenti-Camacho P, Navarro-Gomez ML, et al. S pneumoniae in invasive disease in children in the past 10 years: evolution of resistance and change in serotypes. Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
23. Givon-Lavi N, Greenberg D, Dagan R. Effect of a reduced dose infant schedule of the 7-valent pneumococcal conjugate vaccine (PCV7) on nasopharyngeal pneumococcal carriage (NP-PNC-CARR). Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
24. Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Howitz MF, Andersen PH, et al. Effectiveness of pneumococcal conjugate vaccination on invasive pneumococcal disease in children after its introduction in the Danish Childhood Vaccination Programme. Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
25. François M, Romain O, Lery T, Nachit-Ouinekh F. Acute otitis media burden during the first six years of life in France in 2008. Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
26. Deceuninck G, De Wals P, De Serres G, Boulianne N. Effectiveness of pneumococcal conjugate vaccine (PCV) against invasive pneumococcal disease (IPD): results of a case-control study in Quebec, Canada. Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
27. Vestrheim DF, Aaberge IS, Høiby EA, Caugant DA. Replacement of pneumococcal serotypes among colonised children following introduction of PCV-7 in the Norwegian Vaccination Programme. Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
28. Klok R, Strutton DR, Postma M, Earnshaw SR, Farkouh RA, Public health and economic impact of 13-valent pneumococcal conjugate vaccination in the Netherlands. Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
29. Strutton DR, Kuchenbecker U, Earnshaw SR, Farkouh R. Impact of 13-valent pneumococcal conjugate vaccination on costs and outcomes in Germany and the United States. Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
30. Stoykova B, Strutton DR, Earnshaw SR, Farkouh R. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination elative to 7-valent pneumococcal conjugate vaccination in the United Kingdom (UK). Poster presented at: 27th annual meeting of the European Society for Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.